Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | MASP2 | O00187 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lefradafiban SCHEMBL7080546 | 1.00 | ITGB3 (0.62) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7283791 | 0.94 | ITGB3 (0.57) | ITGB3ITGA2BKDM4EIRAK4HRH3 | |
| SCHEMBL7284195 | 0.94 | ITGB3 (0.57) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7284983 | 0.93 | ITGB3 (0.58) | ITGB3ITGA2BIRAK4HRH3MASP2 | |
| SCHEMBL7282312 | 0.93 | ITGB3 (0.58) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7285046 | 0.92 | ITGB3 (0.73) | ITGB3ITGA2BIRAK4LTA4HHRH3 | |
| SCHEMBL7281873 | 0.92 | ITGB3 (0.55) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7304269 | 0.91 | ITGB3 (0.54) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7275650 | 0.91 | ITGB3 (0.63) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7284255 | 0.91 | ITGB3 (0.56) | ITGB3ITGA2BMASP2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8715920-B2 | Composition for preserving platelets during photosensitization | BIOVEC TRANSFUSION, LLC (US) | 2014-05-06 | — | — | US | claimed |
| US-20110311532-A1 | INHIBITION OF COMPLEMENT AND CELLULAR ACTIVATION | NOVELMED THERAPEUTICS, INC. | 2011-12-22 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100041587-A1 | COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION | PORTER R STEPHEN | 2010-02-18 | — | — | US | claimed |
| EP-1411932-B1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER SCHERING PHARMA AG (DE) | 2010-02-10 | — | — | EP | claimed |
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| JP-2009511543-A | — | — | 2009-03-19 | — | — | JP | claimed |
| US-20020068719-A1 | Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-06 | — | — | US | claimed |
| EP-1189663-A2 | SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, FOR PREVENTING AND TREATING THROMBOEMBOLIC DISORDERS | Du Pont Pharmaceuticals Company (US) | 2002-03-27 | — | — | EP | claimed |
| US-6346517-B1 | ADMINISTERING TINZAPARIN AND ROXIFIBAN | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-12 | — | — | US | claimed |
| JP-2001524534-A | — | — | 2001-12-04 | — | — | JP | claimed |
| EP-1035868-A1 | USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION | Wiemann, Gundula (DE) | 2000-09-20 | — | — | EP | claimed |
| WO-2000053168-A2 | SYNERGY BETWEEN LOW MOLECULAR WEIGHT HEPARIN AND PLATELET AGGREGATION INHIBITORS, FOR PREVENTING AND TREATING THROMBOEMBOLIC DISORDERS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-09-14 | — | — | WO | claimed |
| WO-1999027962-A1 | USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION | WIEMANN GUNDULA (DE) | 1999-06-10 | — | — | WO | claimed |
| EP-0483667-B1 | Cyclic imino derivatives, process for their preparation and drugs containing them | THOMAE GMBH DR K (DE) | 1998-02-04 | — | — | EP | claimed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | claimed |
| EP-0483667-A2 | Cyclic imino derivatives, process for their preparation and drugs containing them | Dr. Karl Thomae GmbH (DE) | 1992-05-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | FGB, F13B, SERPINC1 | ITGB3 102/4885ITGA2B 19/4885KDM4E 1429/4885 |
| US-20020068719-A1 | Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders | SERPINC1, SELP, F13B | ITGB3 30/4885ITGA2B 20/4885KDM4E 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.